Silk Road Medical Inc. (SILK) Reports In-Line Q2 EPS

Silk Road Medical Inc. (NASDAQ: SILK) reported Q2 EPS of ($0.44), in-line with the analyst estimate of ($0.44). Revenue for the quarter came in at $33.2 million versus the consensus estimate of $31.04 million.

“We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility,” said Erica Rogers, CEO of Silk Road Medical. “We also gained meaningful market share through strong physician utilization as we continue to establish TCAR as the minimally-invasive standard of care in stroke prevention, evidenced by recently eclipsing 50,000 global TCAR procedures.”

For earnings history and earnings-related data on Silk Road Medical Inc. (SILK) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Laird Superfood, Inc. (LSF) Misses Q2 EPS by 22c ; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c